Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals Inc. develops biotechnology drug candidates through a biology-centric discovery engine that combines disease biology and protein engineering. Company news has centered on clinical and regulatory updates for its pipeline, including NGM707, a dual ILT2/ILT4 antagonist antibody evaluated in advanced or metastatic solid tumors, and aldafermin development in primary sclerosing cholangitis and other rare-disease strategy discussions.
Recurring updates also include oncology conference presentations, clinical-data posters, operating and financial results, governance matters, capital-structure disclosures, shareholder voting matters and material agreements. Corporate-action news includes the completed cash tender offer by an affiliate of The Column Group for shares of NGM Bio not already held by affiliates and certain other stockholders.
NGM Biopharmaceuticals, Inc. (NGM), a biotechnology company, announced that CEO David J. Woodhouse, Ph.D., will present an overview and business update at two upcoming virtual investor conferences. The first is the Raymond James LILRB/ILT Symposium on April 26, 2022, at 1:30 PM ET, followed by the B. Riley Securities' 2022 Virtual Neurology & Ophthalmology Conference on April 28, 2022, at 10:30 AM ET. Live webcasts will be available on NGM’s website, with replays archived for 30 days.
NGM831 and NGM438, NGM Bio’s myeloid reprogramming antibody candidates targeting stromal checkpoints, will be featured in the second of a four-part series called the “Explorer Series.” This virtual event is scheduled for April 27, 2022, from 11:00 am to 12:30 pm ET. Presenters include NGM Bio's CEO, David Woodhouse, alongside Dr. Don Gibbons from MD Anderson Cancer Center. The session will explore how these candidates may enhance anti-tumor immunity. Future sessions will cover NGM707 and NGM621. A live webcast will be available on NGM Bio’s website.
NGM Biopharmaceuticals, Inc. (NGM) announced details about its myeloid checkpoint inhibitor portfolio at the AACR Annual Meeting, focusing on three candidates: NGM707, NGM831, and NGM438. These candidates aim to disrupt immune suppression in tumors by targeting receptors like ILT3 and LAIR1. NGM707 is currently in a Phase 1/2 trial, while NGM831 and NGM438 are set to enter clinical trials soon. Initial data for NGM707 is expected in the second half of 2022, promising advancements in cancer treatment.
NGM Biopharmaceuticals (NGM) has initiated a Phase 1/1b trial for NGM831, an ILT3 antagonist antibody, targeting advanced solid tumors. This trial aims to enroll up to 80 patients to evaluate safety and efficacy, including its use with KEYTRUDA® (pembrolizumab). NGM831 is part of NGM's broader myeloid reprogramming portfolio, which includes NGM707 and NGM438, emphasizing innovative strategies to enhance anti-tumor immunity. NGM aims to have all three programs in clinical stages by mid-2022, with plans for robust biomarker strategies to optimize patient selection.
NGM Biopharmaceuticals (NGM), a biotech company, will host the first of its four-part Explorer Series virtual R&D events on March 30, 2022. From 11:00 am to 12:15 pm ET, the event will showcase NGM's productive discovery engine, featuring presentations from CEO David Woodhouse and CSO Jin-Long Chen. The series will introduce a preclinical program and subsequent sessions will cover ongoing therapeutic candidates: NGM707, NGM831, NGM438, and NGM621. Live webcasts will be available on NGM's website, with replays archived for a year.
NGM Biopharmaceuticals (NGM) announced that its research on myeloid reprogramming and checkpoint inhibition programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. Key presentations will include NGM707, currently in a Phase 1/2 trial, focusing on immune suppression reversal. Additionally, preclinical findings for NGM831 and NGM438, both set to enter Phase 1 trials in 2022, will be highlighted. These programs aim to enhance immune responses in tumors, showcasing NGM’s innovative drug discovery capabilities.
NGM Bio reported significant advancements in its clinical pipeline during Q4 2021, including obtaining Fast Track designation for NGM621 targeting geographic atrophy due to age-related macular degeneration. The company completed enrollment in the Phase 2b ALPINE 4 trial for aldafermin, with results expected in H1 2023. Financially, NGM Bio reported a net loss of $27.2 million for Q4 and $120.3 million for 2021, but saw a cash balance increase to $366.3 million, sufficient to fund operations into H1 2024.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals (NGM) announces CEO David J. Woodhouse will participate in the Cowen 42nd Annual Health Care Conference on March 7, at 10:30 am ET. The presentation will focus on the company's oncology portfolio and provide a comprehensive business update. Interested parties can watch a live webcast on NGM's website, which will be available for replay for 30 days post-event. NGM is dedicated to developing transformative therapies targeting cancer, retinal diseases, and metabolic disorders.
NGM Biopharmaceuticals, Inc. (NGM) announced that the FDA has granted Fast Track designation to its monoclonal antibody candidate, NGM621, designed to inhibit complement C3 for treating geographic atrophy caused by age-related macular degeneration. This designation is pivotal as it accentuates the urgent medical need for effective therapies in this area. NGM621 is currently being evaluated in the Phase 2 CATALINA study, with topline data anticipated in Q4 2022. GA affects approximately one million patients in the U.S., and there are no existing FDA-approved treatments.
NGM Biopharmaceuticals (NGM) announced a presentation by CEO David J. Woodhouse, Ph.D., at two upcoming investor conferences. The B. Riley Virtual Annual Oncology Investor Conference will take place on January 27, 2022, at 2:30 PM ET, followed by the SVB Leerink’s 11th Annual Global Healthcare Conference on February 18, 2022, at 1:40 PM ET. Live webcasts will be accessible via NGM's website, with replay available for 30 days post-event. NGM focuses on developing transformative therapeutics for cancer, retinal diseases, and liver/metabolic diseases.